Trial Information
Circulating Tumor Cells Identification in Advanced Stage Non-small Cell Lung Cancer
Inclusion Criteria:
- Advanced stage NSCLC (stages IIIB, and IV) with measurable or evaluable disease at
diagnosis.
- Age ≥ 18 years.
- Measurable or evaluable disease according to RECIST criteria.
- Ability to sign informed consent.
Exclusion Criteria:
- Prior cancers within 5 years, except for non-melanoma skin cancers, and in situ
cervical cancers.
- Prior chemotherapy, radiation or surgery for lung cancer.
- Inability to comply with study and/or follow-up procedures.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Identification of circulating tumor cells in locally advanced, and metastatic non-small cell lung cancer.
Outcome Description:
Circulating tumor cells will be search with the Veridex method, and a value per 7.5 f blood will be recorded.
Outcome Time Frame:
18 months
Safety Issue:
No
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
2012-A00135-38
NCT ID:
NCT01658332
Start Date:
June 2012
Completion Date:
Related Keywords:
- Stage IIIB Non Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer
- lung cancer
- circulating tumor cells
- prospective
- monocentrique trial
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Neoplastic Cells, Circulating